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Abstract
Background: To describe how frequently harm is reported in the abstract of high impact factor
medical journals.
Methods: Design and population: We carried out a blinded structured review of a random sample
of 363 Randomised Controlled Trials (RCTs) carried out on human beings, and published in high
impact factor medical journals in 2003. Main endpoint: 1) Proportion of articles reporting harm in
the abstract; and 2) Proportion of articles that reported harm in the abstract when harm was
reported in the main body of the article. Analysis: Corrected Prevalence Ratio (cPR) and its exact
confidence interval were calculated. Non-conditional logistic regression was used.
Results: 363 articles and 407 possible comparisons were studied. Overall, harm was reported in
135 abstracts [37.2% (CI95%:32.2 to 42.4)]. Harm was reported in the main text of 243 articles
[66.9% (CI95%: 61.8 to 71.8)] and was statistically significant in 54 articles [14.9% (CI95%: 11.4 to
19.0)]. Among the 243 articles that mentioned harm in the text, 130 articles [53.5% (CI95% 47.0
to 59.9)] reported harm in the abstract; a figure that rose to 75.9% (CI95%: 62.4 to 86.5) when the
harm reported in the text was statistically significant. Harm in the abstract was more likely to be
reported when statistically significant harm was reported in the main body of the article [cPR =
1.70 (CI95% 1.47 to 1.92)] and when drug companies (not public institutions) funded the RCTs
[cPR = 1.29 (CI95% 1.03 to 1.67)].
Conclusion: Abstracts published in high impact factor medical journals underreport harm, even
when harm is reported in the main body of the article.
Background
Adherence to the best clinical evidence has become an
important guiding principle in both the medical and
health policy decision-making processes. However, con-
cern is growing about the way evidence, and particularly
harm, is presented to doctors and policy makers particu-
larly because benefit has the propensity to be reported
more frequently than harm [1-3], especially when con-
flicts of interest are present (e.g. when drug companies
fund research) [4-7]. Recent research has shown how trial
reports fail to either define or record adverse events [8,9]
or only partially report them [10].
Because of its relevance in medical decision making [11-
17], quality of reporting abstracts, and particularly the
way harm is reported, has been considered an important
issue [18-20]. In fact, besides its generic recommendation
in 2004 [21], CONSORT initiative has recently published
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a new statement to better report journal and conference
abstracts, including a specific reference to harm [22,23].
Little is known, however, about the way abstracts report
harm in phase III and IV randomized controlled trials
published in high impact journals, those considered gold
standard for clinical evidence and therefore, those with
the highest capacity to influence medical decision mak-
ing. Our objective was to describe how frequently harm is
reported in the abstracts of high impact factor medical
journals.
Methods
Design
A blinded structured review of abstracts reporting original
clinical research on human beings published in high
impact factor medical journals was carried out.
Population and setting
A purposive sample of journals was selected based on
their 2003 impact factor (Figure 1). Excluded from the sam-
ple were: Phase I and phase II RCTs, factorial designs, eco-
nomic evaluations and RCTs assessing process measures
(instead of health outcome endpoints). Those RCTs ful-
filling inclusion criteria were sorted by their PMID
number. A consecutive id number from 1 to 363 was
assigned. Then, a random numbers table was used to
recover the sample of 2003 RCTs to be studied (See Addi-
tional file 1). A PubMed search strategy was used to
retrieve RCTs (Table 1).
Main endpoint
Two main endpoints were examined in this work: 1) the
proportion of RCTs reporting or quantifying harm in the
abstract; and 2) the proportion of RCTs that mention or
quantify harm in the abstract when harm was reported in
the main body of the article. Harm was defined as any
possible adverse consequence of an intervention or ther-
apy [21].
Other studied predictors
We considered as explanatory factors: a) funding source
(drug or device companies vs public institutions); b) use
of placebo as control group; c) the sample size (using the
median value, 200 patients, as a threshold); d) the main
endpoint direction of effect (defined as favouring, being
neutral or opposing the intervention); e) clinical signifi-
cance of harm in the text (using mortality vs no mortality
as a proxy); and f) whether the harm reported in the main
text was statistically significant (yes vs no).
Data abstraction
An instrument was developed ad hoc to retrieve key infor-
mation from each article. Its construct and face validity
was assessed by two independent researchers, blinded to
the study hypothesis and the RCTs authors and journals.
Once the tool was designed, information from each article
was obtained following a three steps method. In the first
step, one of us (EBD) selected the articles regarding the
inclusion criteria and entered the information about
topic, treatment groups, and number of treatment arms.
Secondly, two trained junior researchers, blinded to the
hypothesis of the study received an electronic copy of each
article – any single reference to the authors and to the
journal was masked- and retrieved all the remaining infor-
mation using the developed tool. In order to control inter-
observer reliability, accuracy between observers was eval-
uated before (pilot study) and during the research period.
Accuracy ranked from 73% to 82% in main variables. Dis-
agreement was resolved by a third blinded observer using
consensus when necessary.
Analysis
Descriptive measures and Exact confidence intervals with
α-error equalling 5% were calculated. In order to assess
the effect of predictors over the main endpoints, bivariate
non-conditional logistic regression was used. Due to the
high prevalence of the outcome of interest a Corrected
Prevalence Ratio (cPR) was applied using the method sug-
gested by Zhang [24,25]. STATA/SE version 8.0 was used
to perform analysis.
Results
765 RCTs met the study inclusion criteria. A random sam-
ple of 363 articles was selected for review. Since 42 articles
had more than one treatment arm, 407 possible compar-
isons were considered. (Figure 1 details exclusions).
The vast majority of RCTs studied therapeutic interven-
tions (89%) and signs or symptoms were considered the
main endpoint in over 60% of studies. 52% of articles
used placebo as a control group, 51% of articles had fewer
than 200 patients (total sample size) and the plurality of
articles favoured intervention arm (41%). Of note, 25% of
abstracts reported no quantitative information on the
impact of the intervention on the primary study endpoint.
Harm was reported or quantified in 135 abstracts [37.2%
(CI95%:32.2% to 42.38%)], 40% of them (54 out of 135)
used some kind of numerical data: 33 abstracts reported
either "p values" (27 articles) or confident intervals (6
articles). The remaining 21 abstracts referred to harm in
terms of percentage (or mean) of events in each arm,
though no statistical information was offered. When no
numerical data was reported (81 articles) unspecific
expressions like "there were no differences in adverse events"
were used. In addition, harm was reported in the main
text of 243 articles [66.9% (CI95%: 61.8 to 71.9)] and wasBMC Medical Research Methodology 2008, 8:14 http://www.biomedcentral.com/1471-2288/8/14
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statistically significant in 54 articles [14.9% (CI95%: 11.4
to 19.0)].
Among the articles that reported harm in the text, 130 arti-
cles [53.5% (CI95% 47.0% to 59.9%)] reported harm in
the abstract. 41 articles [75.9% (CI95%:62.4% to 86.5%)]
reported harm in the abstract when harm in the text was
reported as statistically significant (Additional details are
shown in Figure 2). When the 407 different comparisons
(instead of studies) were analysed, figures were similar.
Table 2 shows results from bivariate analyses. A very
strong relationship between reporting harm in the text
and in the abstract (cPR = 8.71) was found; however, this
relationship was not so important when either statistical
significance (cPR = 1.7) or clinical relevance were consid-
ered (cPR = 1.43). On the other hand, where funding
sources were concerned, harm in the abstract was less
likely to be reported when public institutions (as opposed
to companies) funded the RCTs (cPR = 0.77). The remain-
ing factors did not show a statistically significant relation-
ship with the probability of reporting harm in the
abstract.
Sample selection flow diagram Figure 1
Sample selection flow diagram.
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When logistic regression was applied to the articles which
reported harm in the text, funding source and reporting
mortality in the body of the article did not remain in the
model. Only reporting statistically significant harm in the
text was related to the probability of reporting harm in the
abstract [cPR = 1.25 (CI95% 1.12 to 1.38)].
Discussion
We have found that 33% of the articles in our sample did
not report harm in the text; additionally, 46.5% of the
studies that documented harm in the body of the article
failed to report these harm in the abstract. Unfortunately,
although different approaches to the study of abstracts
have been developed, there is no similar research with
which compare the coherence and consistency of these
results.
With regard to the underlying factors of these results, we
have found that the probability of harm being reported in
the abstract depends on harm reporting in the body of the
article, particularly, when statistically significant harm
occurs. This finding is consistent with previous evidence
in which researchers themselves suggest that the lack of
statistical significance is a potential cause of failure in
reporting harm [10]. In the same article, however, authors
suggest that another important factor must be considered:
Proportion of randomized controlled trials in high profile medical journals reporting harm in abstracts Figure 2
Proportion of randomized controlled trials in high profile medical journals reporting harm in abstracts.
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Table 1: RCT search strategy
#1 randomized controlled trial. pt
#2 limit #1 to (clinical trial, phase i or clinical trial, phase ii)
#3 #1 not #2
#4 limit #3 to yr = 2003
#5 limit #4 to human
#6 limit #5 to journal article
#7 comment. pt
#8 #6 not #7
#9 #8 not letter. ptBMC Medical Research Methodology 2008, 8:14 http://www.biomedcentral.com/1471-2288/8/14
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clinical significance of harm. Some may consider that we
have overlooked a specific assessment of this factor. Our
study has certainly not assessed clinical significance itself
but we have used a proxy "reporting mortality in the text as
an adverse event", which was moderately associated. How-
ever, "clinical significance of harm" did not remain in
logistic models when statistically significant effects were
considered. This may suggest that, in our sample, report-
ing harm in abstracts is driven more by statistics than by
clinical significance of harm.
One other result deserves further attention. As we men-
tioned above, the vast majority of research has demon-
strated that articles funded by industry tend to favour the
intervention group; however, when a study was funded by
industry harm being reported in the abstract was
favoured, even though phase IV RCTs were included in the
sample. Some explanations should be argued. On the one
hand, studies funded by commercial sources have a larger
sample size than those funded by public institutions and,
therefore, they have more statistical power to detect
adverse events if they exist. In actual fact, while the mean
sample size of RCTs sponsored by industry reached 1619
patients, mean sample size of publicly funded RCTs
counted for 793 patients. Certainly, when we controlled
for study size, the effect of funding was no longer signifi-
cant. Another alternative explanation is related to the
strict control that industry faces when developing a new
drug. Industry is required by National Agencies to collect
and report efficacy and safety. This requirement contrasts
with a more relaxed policy in the case of public funded
RCTs in which authors are only asked to declare their own
conflict of interests.
Limitations
Some limitations of our study must be reported. Firstly, as
a purposive sample of journals, our results must only be
referred to the journals we have studied. In any case, we
have selected high profile literature (in terms of impact
factor and professional acknowledgement) under the
hypothesis that these journals should accomplish high
standards of reporting more frequently than others. If this
hypothesis is true, worse results should be expected in the
remaining literature but our data is not able to state this.
Secondly, it could be argued that factors exist which were
not considered in this study. Even though this could be
true, the vast majority of variation in reporting harm in
the abstract was explained by the presence of harm in the
body of the article (ROC curve area equals 0.73 when
logistic models were fitted). Therefore, the potential effect
of other factors would be residual in any case. Finally, due
to the fact that we used an instrument to retrieve the infor-
mation from the RCTs, and two independent blinded
reviewers were involved, misclassification could be
argued as a possible source of bias. Even though bias is
possible, agreement between both reviewers was assessed
before consensus and they reached an accuracy index over
75% in the main variables.
Implications
Abstracts are the most widely read summaries of research
findings and are an important source of information for
clinicians and policy makers; particularly abstracts of
phase III&IV RCTs published in high profile journals.
Additionally, the electronic abstract of almost all pub-
lished articles can easily be obtained from electronic data-
bases. Both elements combined with the fact that a third
of the articles in our sample did not report harm and more
than half the studies that documented harm in the body
of the article failed to report this harm in the abstract
strongly support the reporting policies suggested by the
two latest CONSORT statements; particularly in those
aspects related to appropriate database indexing and
information retrieval [21] and reporting important
adverse (or unexpected) effects of an intervention [22].
However, our results suggest a new perspective to the
statement because the probability of reporting harm in
the abstract is mainly driven by the statistical significance
rather than the "clinical relevance" of the finding. Proba-
bly, a more specific statement will be needed in order to
determine what "important adverse (or unexpected)
effects of an intervention" mean for the statement:
Table 2: Factors influencing harm reported in the abstract
cPR (CI95%)
Funding*
drug or device companies 1
public institutions 0.77 (0.60 to 0.97)
Placebo
other control 1
placebo 0.97 (0.81 to 1.13)
Sample size
less than 20 1
equals or more than 200 1.14 (0.96 to 1.33)
Direction of effect
beneficial to intervention 1
neutral or against the intervention 1.00 (0.83 to 1.19)
Harm in text
no harm in text 1
harm in text 8.71 (5.90 to 12.01)
Clinical significance of harm
no mortality nor composite in text 1
mortality or composite in text 1.43 (1.22 to 1.65)
Harm in text statistically significant
not statistically significant 1
statistically significant 1.70 (1.47 to 1.92)
cPR: Prevalence Ratio estimated by logistic regression, and corrected 
by applying the method proposed by Zhang [24]; CI: Confidence 
Intervals with error type I equals 5%; *363 articles except for funding 
in which sample size was n = 226BMC Medical Research Methodology 2008, 8:14 http://www.biomedcentral.com/1471-2288/8/14
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whether it be statistical significance (which is influenced
by the statistical power of the RCTs to detect harm), or
clinical importance (which entails a more difficult defini-
tion).
Finally, our study suggests that to better reach CONSORT
objectives, a new rationale of reporting harm should be
adopted, resting on the need for clinicians and policy
makers to understand that almost all interventions have
both benefits and harm.
Conclusion
In conclusion, abstracts published in high impact factor
medical journals underreport harm even when the articles
provide information in the main body of the article. The
results should encourage researchers, public funding insti-
tutions and editors to pay more attention to the way ben-
efits and harm are reported.
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